Nasopharyngeal carcinoma · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Oxaliplatin and RT Variant #01 | — | R 5 693 | 42d | — | — | ~1 | ~R 5 693 PFS proxy · indirect | 1 |
Carboplatin and RT Variant #01 | — | R 3 746 | 42d | — | ~22.4 mo | ~1 | ~R 3 746 PFS proxy · indirect | 1 |
Cisplatin and Fluorouracil (CF) and RT Variant #01 | — | R 1 774 | 17d | — | ~16.5 mo | ~1 | ~R 1 774 PFS proxy · indirect | 1 |
Cisplatin and RT Variant #01 | — | R 588 | 49d | — | — | ~1 | ~R 588 PFS proxy · indirect | 3 |
Radiation therapy N/A - radiation | — | — | 49d | — | — | — | — | 3 |
Nedaplatin and RT Variant #01 Partial | — | — | — | ~30.0 mo | — | ~1 | — | 1 |
6 of 6 regimens shown